Aernoud Fiolet

308 Chapter 12 REFERENCES 1. Leung YY, Hui LLY, Kraus VB. Colchicine—Update on mechanisms of action and therapeutic uses. Semin Arthritis Rheum 2015;45(3):341–50. 2. Paschke S, Weidner AF, Paust T, Marti O, Beil M, Ben‐Chetrit E. Technical advance: Inhibition of neutrophil chemotaxis by colchicine is modulated through viscoelastic properties of subcellular compartments. J Leukoc Biol 2013;94(5):1091–6. 3. Cronstein BN, Molad Y, Reibman J, Balakhane E, Levin RI, Weissmann G. Colchicine alters the quantitative and qualitative display of selectins on endothelial cells and neutrophils. J Clin Invest 1995;96(2):994–1002. 4. Martinon F, Pétrilli V, Mayor A, Tardivel A, Tschopp J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 2006;440(7081):237–41. 5. Hemkens LG, Ewald H, Gloy VL, et al. Cardiovascular effects and safety of long-term colchicine treatment: Cochrane review and meta-analysis. Heart 2016;102(8):590–6. 6. Stewart S, Yang KCK, Atkins K, Dalbeth N, Robinson PC. Adverse events during oral colchicine use: a systematic review and meta-analysis of randomised controlled trials. Arthritis Res Ther 2020;22(1):1–15. 7. Finkelstein Y, Aks SE, Hutson JR, et al. Colchicine poisoning: the dark side of an ancient drug. Clin Toxicol 2010;48(5):407–14. 8. Solak Y, Atalay H, Biyik Z, et al. Colchicine Toxicity in End-Stage Renal Disease Patients. Am J Ther 2014;21(6):e189–95. 9. Tardif J-CC, Kouz S,Waters DD, et al. Efficacy and Safety of Low-Dose Colchicine afterMyocardial Infarction. N Engl J Med 2019;381(26):2497–505. 10. Nidorf SM, Fiolet ATL, Mosterd A, et al. Colchicine in Patients with Chronic Coronary Disease. N Engl J Med 2020;383:1838–47. 11. Nidorf SM, Fiolet ATL, Eikelboom JW, et al. The effect of low-dose colchicine in patients with stable coronary artery disease: The LoDoCo2 trial rationale, design, and baseline characteristics. Am Heart J 2019;218:46–56. 12. Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014;63(25 Part B):2889–934. 13. Colloca L, Barsky AJ. Placebo and nocebo effects. N Engl J Med 2020;382(6):554–61. 14. Imazio M, Bobbio M, Cecchi E, et al. Colchicine in addition to conventional therapy for acute pericarditis: results of the COlchicine for acute PEricarditis (COPE) trial. Circulation 2005;112(13):2012–6. 15. Imazio M, Brucato A, Cemin R, et al. A randomized trial of colchicine for acute pericarditis. N Engl J Med 2013;369(16):1522–8. 16. Satiş H,Armağan B, Bodakci E, et al. Colchicine intolerance in FMF patients and primary obstacles for optimal dosing. Turkish J Med Sci 2020;50(5):1337–43. 17. Jenneck C, Juergens U, Buecheler M, Novak N. Pathogenesis, diagnosis, and treatment of aspirin intolerance. Ann Allergy, Asthma Immunol 2007;99(1):13–21. 18. Tournoij E, Peters RJG, Langenberg M, Kanhai KJK, Moll FL. The prevalence of intolerance for low-dose acetylsalicylacid in the secondary prevention of atherothrombosis. Eur J Vasc Endovasc Surg 2009;37(5):597–603.